TLSI · TriSalus Life Sciences, Inc. · Share Buybacks
$4.32
+0.17 (+4.10%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Market Cap
$267.23M
Shares
61.57M
Volume · Oct 2
145.38K
Avg daily vol (3M)
287.52K
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2023-06-30 YTD | $8,479,333 | 10-Q, filed 2023-08-02 |
| 2022-12-31 | $232,371,273 | 10-K, filed 2023-03-22 |